NCT06651970 - Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 4, 2025

Primary Completion Date

August 16, 2030

Study Completion Date

August 16, 2030

Conditions

Chronic Lymphocytic LeukaemiaHeart Failure

Interventions

DRUG

Acalabrutinib

Acalabrutinib Monotherapy

OTHER

Investigator's choice of treatment

control arm treatment type will be defined by the PI prior to randomisation

Trial Locations (23)

10034

NOT_YET_RECRUITING

Research Site, Prague

19104

RECRUITING

Research Site, Philadelphia

20122

RECRUITING

Research Site, Milan

20132

RECRUITING

Research Site, Milan

27100

RECRUITING

Research Site, Pavia

28040

RECRUITING

Research Site, Madrid

28204

NOT_YET_RECRUITING

Research Site, Charlotte

41009

RECRUITING

Research Site, Seville

43210

RECRUITING

Research Site, Columbus

50134

RECRUITING

Research Site, Florence

625 00

NOT_YET_RECRUITING

Research Site, Brno

500 05

NOT_YET_RECRUITING

Research Site, Hradec Králové

09121

RECRUITING

Research Site, Cagliari

06156

RECRUITING

Research Site, Perugia

30-727

RECRUITING

Research Site, Krakow

60-693

NOT_YET_RECRUITING

Research Site, Poznan

08003

RECRUITING

Research Site, Barcelona

BH7 7DW

NOT_YET_RECRUITING

Research Site, Bournemouth

OX3 7LE

RECRUITING

Research Site, Oxford

PL6 8DH

RECRUITING

Research Site, Plymouth

RM7 0AG

RECRUITING

Research Site, Romford

TS19 8PE

NOT_YET_RECRUITING

Research Site, Stockton

B74 3UP

RECRUITING

Research Site, Sutton Coldfield